EA201691070A1 - Новые трициклические соединения в качестве противораковых средств - Google Patents

Новые трициклические соединения в качестве противораковых средств

Info

Publication number
EA201691070A1
EA201691070A1 EA201691070A EA201691070A EA201691070A1 EA 201691070 A1 EA201691070 A1 EA 201691070A1 EA 201691070 A EA201691070 A EA 201691070A EA 201691070 A EA201691070 A EA 201691070A EA 201691070 A1 EA201691070 A1 EA 201691070A1
Authority
EA
Eurasian Patent Office
Prior art keywords
anticative
connections
agents
new tricyclic
new
Prior art date
Application number
EA201691070A
Other languages
English (en)
Other versions
EA032469B1 (ru
Inventor
Дерек Дж. Норрис
Джордж В. Делукка
Ашвиникумар В. Гавай
Клод А. Кеснелль
Патрис Джилл
Дэниэл О'Малли
Уэйн Ваккаро
Фрэнсис И. Ли
Миккел В. Дебенедетто
Эндрю П. Дегнан
Хайкан Фанг
Мэттью Д. Хилл
Хонг Хуанг
Уилльям Д. Шмитц
Джон Е. мл. Старретт
Вен-Чинг Хан
Джон С. Токарски
Сунил Кумар Мандал
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201691070A1 publication Critical patent/EA201691070A1/ru
Publication of EA032469B1 publication Critical patent/EA032469B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к новым трициклическим соединениям, фармацевтически приемлемым композициям, содержащим соединения по настоящему изобретению, и способам применения указанных композиций для лечения различных нарушений.
EA201691070A 2013-12-24 2014-12-23 Новые трициклические соединения в качестве противораковых средств EA032469B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24
PCT/US2014/072031 WO2015100282A1 (en) 2013-12-24 2014-12-23 Tricyclic compounds as anticancer agents

Publications (2)

Publication Number Publication Date
EA201691070A1 true EA201691070A1 (ru) 2016-11-30
EA032469B1 EA032469B1 (ru) 2019-05-31

Family

ID=52293305

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990240A EA201990240A1 (ru) 2013-12-24 2014-12-23 Новые трициклические соединения в качестве противораковых средств
EA201691070A EA032469B1 (ru) 2013-12-24 2014-12-23 Новые трициклические соединения в качестве противораковых средств

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990240A EA201990240A1 (ru) 2013-12-24 2014-12-23 Новые трициклические соединения в качестве противораковых средств

Country Status (33)

Country Link
US (1) US20160318928A1 (ru)
EP (2) EP3466949B1 (ru)
JP (2) JP6466456B2 (ru)
KR (1) KR102457145B1 (ru)
CN (2) CN108558871B (ru)
AR (2) AR099379A1 (ru)
AU (1) AU2014369982B2 (ru)
BR (1) BR112016013744B1 (ru)
CA (1) CA2934953C (ru)
CL (1) CL2016001629A1 (ru)
CY (2) CY1121076T1 (ru)
DK (2) DK3087071T3 (ru)
EA (2) EA201990240A1 (ru)
ES (2) ES2698998T3 (ru)
HR (2) HRP20181849T1 (ru)
HU (2) HUE054183T2 (ru)
IL (1) IL246359B (ru)
LT (2) LT3466949T (ru)
MA (1) MA39211B1 (ru)
MX (1) MX369491B (ru)
MY (1) MY176489A (ru)
NZ (1) NZ722326A (ru)
PE (1) PE20160844A1 (ru)
PH (1) PH12016500953A1 (ru)
PL (2) PL3087071T3 (ru)
PT (2) PT3466949T (ru)
RS (2) RS61479B1 (ru)
SG (1) SG11201605097SA (ru)
SI (2) SI3087071T1 (ru)
TN (1) TN2016000238A1 (ru)
TW (2) TWI736517B (ru)
UY (1) UY35916A (ru)
WO (1) WO2015100282A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134267A1 (en) 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
AR099379A1 (es) * 2013-12-24 2016-07-20 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
AU2015222887B2 (en) * 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
KR20180036974A (ko) 2015-07-16 2018-04-10 바이오엑셀 테라퓨틱스 인코포레이티드 면역조절을 이용하는 암의 치료를 위한 신규한 접근법
CA2999523A1 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
WO2017124934A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的含膦咔啉衍生物
WO2017124936A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的咔啉衍生物
WO2017133681A1 (zh) * 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
IL297201A (en) 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
JP2019534306A (ja) 2016-11-10 2019-11-28 羅欣薬業（上海）有限公司Ｌｕｏｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ（Ｓｈａｎｇｈａｉ） Ｃｏ．， Ｌｔｄ． 窒素含有大員環系化合物、その製造方法、薬物組成物および使用
CN106905347B (zh) * 2017-04-18 2019-04-16 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
WO2020001152A1 (en) 2018-06-25 2020-01-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Tricyclic compounds
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113544129A (zh) * 2019-04-04 2021-10-22 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
WO2021065980A1 (ja) 2019-09-30 2021-04-08 協和キリン株式会社 Ｂｅｔ分解剤
WO2022156757A1 (en) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
AU2022227673A1 (en) * 2021-02-25 2023-08-17 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
SI1879573T1 (sl) 2005-05-10 2013-04-30 Incyte Corporation Experimental Station Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
IN2012DN01920A (ru) 2009-09-03 2015-07-24 Schering Corp
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
AU2010329934B2 (en) 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
TW201141872A (en) 2010-02-26 2011-12-01 Boehringer Ingelheim Int Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
ME03447B (me) 2010-03-04 2020-01-20 Macrogenics Inc Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
TWI651331B (zh) 2010-05-04 2019-02-21 戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
MY162737A (en) 2010-09-09 2017-07-14 Pfizer 4-1bb binding molecules
TWI441824B (zh) * 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (ru) 2011-04-15 2018-03-17
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
EP2762477A1 (en) * 2011-09-28 2014-08-06 Idemitsu Kosan Co., Ltd Material for organic electroluminescent element, and organic electroluminescent element produced using same
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20220162819A (ko) 2012-05-11 2022-12-08 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201501413YA (en) 2012-08-31 2015-03-30 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2014134267A1 (en) * 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9675697B2 (en) * 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
AR099379A1 (es) * 2013-12-24 2016-07-20 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos

Also Published As

Publication number Publication date
ES2857848T3 (es) 2021-09-29
CY1124061T1 (el) 2022-05-27
EP3466949B1 (en) 2020-12-23
DK3087071T3 (da) 2019-01-02
TW201609725A (zh) 2016-03-16
KR20160095168A (ko) 2016-08-10
IL246359A0 (en) 2016-08-31
AU2014369982B2 (en) 2019-04-18
AR123996A2 (es) 2023-02-01
RS61479B1 (sr) 2021-03-31
MX369491B (es) 2019-11-11
HRP20210212T8 (hr) 2021-08-20
ES2698998T3 (es) 2019-02-06
LT3466949T (lt) 2021-03-25
UY35916A (es) 2015-06-30
CN106029663B (zh) 2018-06-01
BR112016013744B1 (pt) 2022-08-30
JP6675501B2 (ja) 2020-04-01
HUE054183T2 (hu) 2021-08-30
PL3466949T3 (pl) 2021-05-31
JP2019070014A (ja) 2019-05-09
IL246359B (en) 2020-04-30
AU2014369982A1 (en) 2016-08-04
MX2016007928A (es) 2016-08-03
JP2017505762A (ja) 2017-02-23
PH12016500953A1 (en) 2016-06-27
EA201990240A1 (ru) 2019-06-28
SG11201605097SA (en) 2016-07-28
KR102457145B1 (ko) 2022-10-19
SI3466949T1 (sl) 2021-03-31
EP3087071A1 (en) 2016-11-02
TN2016000238A1 (en) 2017-10-06
HRP20181849T1 (hr) 2018-12-28
CN108558871B (zh) 2022-02-18
HUE041719T2 (hu) 2019-05-28
SI3087071T1 (sl) 2018-11-30
BR112016013744A2 (ru) 2017-10-03
RS58014B1 (sr) 2019-02-28
US20160318928A1 (en) 2016-11-03
PL3087071T3 (pl) 2019-03-29
WO2015100282A1 (en) 2015-07-02
CY1121076T1 (el) 2019-12-11
MY176489A (en) 2020-08-12
JP6466456B2 (ja) 2019-02-06
CN106029663A (zh) 2016-10-12
EP3466949A1 (en) 2019-04-10
NZ722326A (en) 2019-09-27
TWI726544B (zh) 2021-05-01
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
CA2934953C (en) 2022-09-20
CN108558871A (zh) 2018-09-21
PT3466949T (pt) 2021-02-25
CL2016001629A1 (es) 2017-02-17
TWI736517B (zh) 2021-08-21
EP3087071B1 (en) 2018-09-05
PE20160844A1 (es) 2016-09-03
EA032469B1 (ru) 2019-05-31
CA2934953A1 (en) 2015-07-02
AR099379A1 (es) 2016-07-20
DK3466949T3 (da) 2021-03-15
TW202028203A (zh) 2020-08-01
MA39211B1 (fr) 2019-01-31
HRP20210212T1 (hr) 2021-07-09
PT3087071T (pt) 2018-11-29

Similar Documents

Publication Publication Date Title
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201892147A1 (ru) Бициклические соединения
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201492002A1 (ru) Противовирусные соединения
EA201790781A2 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201690844A1 (ru) Ингибиторы gsk-3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM